文献速递系统性红斑狼疮

系统性红斑狼疮患儿的羟氯喹与免疫抑制剂用药依从性模式及其与后续住院率的关系

Hydroxychloroquine and immunosuppressant adherence patterns and their association with subsequent hospitalization rates among children with systemic lupus erythematosus.
PubMed 文献 · Semin Arthritis Rheum · 2022-06-08

在美国系统性红斑狼疮(SLE)患儿代表性样本中,基于处方索赔数据评估羟氯喹与免疫抑制剂依从性估计的一致性及预测效度。423例新用药者中,羟氯喹充分依从(PDC≥80%)为51-52%,免疫抑制剂为33-45%;羟氯喹不依从与后续住院发生率升高2.9倍相关,免疫抑制剂不依从及两者同时不依从分别与升高5.9倍和5.6倍相关。

要点

  • 羟氯喹充分依从(PDC≥80%)为51-52%,免疫抑制剂为33-45%。
  • 羟氯喹不依从与后续住院发生率升高2.9倍相关(95%CI 1.2-7.1)。
  • 免疫抑制剂不依从及同时不依从分别与住院发生率升高5.9倍和5.6倍相关。

核心结论

  • 在SLE患儿中,羟氯喹依从性不能完全代表其他狼疮药物的依从性,同时评估免疫抑制剂依从性可增加价值。
  • 基于处方索赔的免疫抑制剂依从性指标可预测急性医疗资源使用情况,或可辅助人群管理策略。

研究设计与样本

  • 利用美国Truven Health MarketScan®商业保险与医疗补助索赔数据库(2013-2018年)识别5-18岁SLE患儿。
  • 在羟氯喹和免疫抑制剂新用药者中,计算365天内覆盖天数比例(PDC)以估计各用药组依从性。
  • 采用组内相关系数(ICC)和kappa统计评估依从性估计之间的一致性。
  • 分别采用负二项回归模型估计羟氯喹、免疫抑制剂或两者同时不依从与后续住院之间的关联,并校正基线人口学、疾病严重度和医疗使用情况。

主要发现

  • 共纳入423例羟氯喹/免疫抑制剂新用药者,其中63%为医疗补助受助者。
  • 免疫抑制剂充分依从(PDC≥80%)范围为33%至45%,羟氯喹为51-52%。
  • 羟氯喹与免疫抑制剂依从性之间总体一致性中等,但麦考酚酯(ICC 0.55)优于甲氨蝶呤(ICC 0.27)。
  • 羟氯喹不依从与后续住院发生率升高2.9倍相关(95%CI 1.2-7.1)。
  • 免疫抑制剂不依从和同时不依从分别与住院发生率升高5.9倍(95%CI 2.4-14.6)和5.6倍(95%CI 2.0-15.5)相关。

关键数值与推荐

  • 充分依从定义为PDC≥80%,在365天观察期内计算。
  • 羟氯喹与免疫抑制剂依从性一致性:麦考酚酯ICC 0.55,甲氨蝶呤ICC 0.27。
  • 羟氯喹不依从与后续住院关联:发生率比2.9(95%CI 1.2-7.1)。
  • 免疫抑制剂不依从与后续住院关联:发生率比5.9(95%CI 2.4-14.6)。
  • 同时不依从与后续住院关联:发生率比5.6(95%CI 2.0-15.5)。

临床怎么用

  • 作者认为,在SLE患儿中评估免疫抑制剂依从性可补充羟氯喹依从性评估的价值。
  • 作者认为,基于处方索赔的免疫抑制剂依从性指标可预测急性医疗资源使用,或可辅助人群管理策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Using a representative sample of children with systemic lupus erythematosus (SLE) in the United States, we characterized prescription claim-based hydroxychloroquine and immunosuppressant adherence estimates and evaluated their concurrent and predictive validity. METHODS: We identified children ages 5-18 with SLE in the Truven Health MarketScan® Commercial and Medicaid claims databases (2013-2018). Among new users of hydroxychloroquine and immunosuppressant medications, we calculated proportion of days covered (PDC) over 365 days to estimate adherence by user group (mycophenolate, azathioprine, methotrexate, and any immunosuppressant use). Agreement between adherence estimates was evaluated with intraclass correlation coefficients (ICC) and kappa statistics. Separate negative binomial regression models were used to estimate associations between (a) hydroxychloroquine, (b) immunosuppressant, or (c) concurrent immunosuppressant/hydroxychloroquine non-adherence and subsequent hospitalizations, adjusted for baseline demographics, disease severity, and healthcare utilization. RESULTS: Among 423 new hydroxychloroquine/immunosuppressant users, 63% were Medicaid recipients. Sufficient adherence (PDC≥80%) ranged from 33 to 45% for immunosuppressants vs. 51-52% for hydroxychloroquine. Agreement between hydroxychloroquine and immunosuppressant adherence was modest overall, but better for mycophenolate (ICC 0.55) than methotrexate (0.27). Hydroxychloroquine non-adherence was associated with a 2.9-fold higher incidence of subsequent hospitalizations (95% CI [1.2-7.1]), whereas immunosuppressant and concurrent non-adherence were associated with 5.9 [2.4-14.6] and 5.6-fold [2.0-15.5] increased incidence, respectively. Use of concurrent adherence improved upon estimation of hospitalization risk compared to hydroxychloroquine adherence, but not immunosuppressant adherence alone. CONCLUSIONS: Hydroxychloroquine adherence is an imperfect proxy for adherence to other lupus medications among children with SLE, and therefore assessing immunosuppressant adherence concurrently adds value to hydroxychloroquine adherence assessments. Prescription claims-based immunosuppressant adherence measures are predictive of acute care utilization and may inform population management strategies.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Chang JC, Costenbader KH. Hydroxychloroquine and immunosuppressant adherence patterns and their association with subsequent hospitalization rates among children with systemic lupus erythematosus. Semin Arthritis Rheum. 2022. PMID: 35738041. doi:10.1016/j.semarthrit.2022.152042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。